STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate at the Cowen 43rd Annual Healthcare Conference in Boston, MA. Katherine Stueland, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, March 7, 2023, at 2:50 p.m. ET.
A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
About GeneDx
GeneDx, (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest rare disease data sets.
For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
Investor contact
Tricia Truehart
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media contact
Stephanie Kahan
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$120.72 |
| Daily Change: | 0.60 0.50 |
| Daily Volume: | 876,818 |
| Market Cap: | US$3.470B |
June 23, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
